Q2 2024 EPS Estimates for Oculis Holding AG Lifted by HC Wainwright (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS) – Stock analysts at HC Wainwright upped their Q2 2024 EPS estimates for Oculis in a research note issued on Wednesday, April 24th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.37) per share for the quarter, up from their prior estimate of ($0.41). HC Wainwright currently has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Oculis’ current full-year earnings is ($1.72) per share. HC Wainwright also issued estimates for Oculis’ Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.35) EPS and FY2024 earnings at ($1.44) EPS.

OCS has been the topic of several other reports. Robert W. Baird cut their target price on Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, March 19th. Wedbush restated an “outperform” rating and issued a $29.00 price target on shares of Oculis in a research report on Wednesday, March 6th. Finally, Chardan Capital reissued a “buy” rating and set a $30.00 target price on shares of Oculis in a research note on Tuesday, March 19th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Oculis currently has an average rating of “Buy” and a consensus price target of $29.14.

Oculis Stock Performance

Shares of NASDAQ:OCS opened at $12.02 on Friday. The company has a current ratio of 5.29, a quick ratio of 5.29 and a debt-to-equity ratio of 0.01. Oculis has a 52 week low of $9.05 and a 52 week high of $14.50. The firm’s fifty day moving average is $11.85 and its 200-day moving average is $11.24.

Oculis (NASDAQ:OCS) last posted its earnings results on Monday, March 18th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Barclays PLC purchased a new stake in Oculis in the 2nd quarter valued at about $44,000. Wolverine Asset Management LLC bought a new stake in Oculis during the third quarter worth $77,000. Compagnie Lombard Odier SCmA boosted its position in Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after purchasing an additional 30,750 shares during the last quarter. abrdn plc bought a new position in Oculis in the 4th quarter valued at $15,980,000. Finally, Searle & CO. purchased a new stake in shares of Oculis during the 4th quarter valued at $112,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.